Skip to content
The Policy VaultThe Policy Vault

Krazati (adagrasib tablets - Mirati Therapeutics) — Cigna

Small Bowel Adenocarcinoma

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has advanced or metastatic disease
  • Patient has KRAS G12C mutation-positive disease

Approval duration

1 year